Opposite Cell Differentiation Program for Degenerated Organ Treatment

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current cell-based therapies for degenerative diseases face challenges such as tumorigenicity, dedifferentiation, transformation into organ-foreign cells, loss of functionality, and ethical concerns, particularly with stem cells, due to their phenotypical flexibility and genetic manipulation limitations, which hinder achieving a stable, permanently functional phenotype resistant to degenerative environments.

Innovation Solution

The concept of the 'opposite cell differentiation program' (OCDP) involves identifying cell populations with opposite activation states or regulation mechanisms in donor organs to transplant cells that have opposite phenotypes to the diseased organ, utilizing phenotypically stable differentiating or differentiated cells like hepatic stellate cells and mesangial cells, which can resist pathological pressures and promote regeneration by producing trophic factors.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If stem cells are used for cell replacement therapy, then the regeneration capacity of damaged organs is improved, but tumorigenicity and dedifferentiation risks increase

Engineering Contradiction:
Improveregeneration capacityVSAvoidtumorigenicity
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies the inversion principle by using differentiated cells from organs with opposite pathological states instead of undifferentiated stem cells. For example, using cells from a healthy organ to treat a degenerated organ, or using cells from an organ with a different differentiation state. This reverses the conventional approach of using undifferentiated cells and instead employs already differentiated cells that have opposite phenotypic characteristics to the diseased state, thereby avoiding tumorigenicity while maintaining regenerative capacity.

Inventive Principle:
Principle #13The other way round (Inversion)

2Reliability

If genetically manipulated cells are used to enhance regenerative properties, then the therapeutic effect is improved, but safety and controllability are reduced

Engineering Contradiction:
Improvetherapeutic effectVSAvoidgenetic manipulation complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent extracts and utilizes the natural regenerative properties inherent in differentiated cells from opposite organ states without requiring genetic manipulation. By selecting cells that naturally possess opposite phenotypic characteristics to the diseased organ, the invention eliminates the need for complex genetic engineering while still achieving enhanced therapeutic effects through the cells' intrinsic properties.

Inventive Principle:
Principle #2Taking out (Extraction)

3Adaptability or versatility

If phenotypically flexible cells are used for transplantation, then adaptability to different organs is improved, but stability of function is reduced

Engineering Contradiction:
Improveorgan compatibilityVSAvoidphenotypic stability
Core Design Contradiction:
Adaptability or versatilityVSStability of the object's composition

Solution Approach 1:

The patent changes the key parameter from phenotypic flexibility to phenotypic opposition. Instead of selecting cells based on their ability to adapt to any organ, the invention selects cells based on their having opposite phenotypic characteristics to the diseased organ. This parameter change ensures that the transplanted cells bring counterbalancing properties that stabilize the pathological environment while maintaining functional adaptability to the specific organ needs.

Inventive Principle:
Principle #35Parameter changes

Data Source

PatentEP2201105B1Use of the opposite cell differentiation program (OCDP) for the treatment of degenerated organs in the pathological state
Publication Date: 2016.05.18 UNIV LEIPZIG
  • EP2201105B1 patent drawingFigure 1
  • EP2201105B1 patent drawingFigure 2
  • EP2201105B1 patent drawingFigure 3

AI summary

The present invention relates to a method for the treatment of organs which are degenerative and /or in the pathological state by means of the use of cells, which are phenotypically stably differentiating or differentiated but not necessarily ultimately predetermined with respect to development, from a donor organ selected according to the principles of the opposite cell differentiation program (OCDP) and also to the use of cells of this type for the treatment or for the production of a drug for treatment of the same. Furthermore, the present invention relates to pharmaceutical agents comprising suitable phenotypically stable cells, cells of a first organ which is different from the second organ with respect to organ type thereby being used, which, in the normal physiological state with respect to a predetermined set of expressed genes and/ or phenotypical properties, have opposite properties to the second cells in the normal physiological state.